Douglas Clark Wurth Acquires 12,500 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Douglas Clark Wurth acquired 12,500 shares of the firm’s stock in a transaction that occurred on Saturday, March 14th. The shares were bought at an average cost of $2.00 per share, for a total transaction of $25,000.00. Following the purchase, the director owned 12,608 shares of the company’s stock, valued at approximately $25,216. The trade was a 11,574.07% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Bluejay Diagnostics Stock Down 0.6%

BJDX opened at $1.71 on Wednesday. The firm has a market cap of $1.76 million, a P/E ratio of -0.15 and a beta of 0.72. Bluejay Diagnostics, Inc. has a 52 week low of $1.62 and a 52 week high of $16.68. The business’s fifty day simple moving average is $1.89 and its 200 day simple moving average is $3.14.

Bluejay Diagnostics (NASDAQ:BJDX) last released its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bluejay Diagnostics currently has an average rating of “Sell”.

Hedge Funds Weigh In On Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics at the end of the most recent reporting period. Hedge funds and other institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.